Clinical Effects and Safety of Tongxieyaofang on Diarrhea Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized Trails

Table 1

The baseline characteristics of included trails.

Author	Year	Sample Size (I/C)	Control Group	Age (years)	IBS-D Duration	Intervention	Outcome Measurements
				(I/C)	(I/C)	Duration
L.F. An	2017	32/32	Dioctahedral smectite+pinaverium bromide	34.8±3.8/34.2±3.6	3.06±0.34/2.97±0.32y	4w	①+②+③+④
X.Y. Cao	2015	46/46	Pinaverium bromide+oryzanol	18-56/16-58	2.5/2.2y	1m	①+⑦
Y.L. Chen	2014	35/35	Pinaverium bromide	40.23±14.85/38.57±12.49	NR	1m	①+⑤
Y.X. Chen	2014	30/30	Trimebutine+Bifid Triple Viable Capsules	43.1±10.2	NR	4w	①+②+④
Z.J. Chen	2012	30/30	Trimebutine	32.0±1.7/31.0±5.9	2.6±0.65/2.5±0.77y	30d	①+⑤+⑥
H. Dong	2012	60/60	Pinaverium bromide	26-57/28-53	2-11/1.5-10y	4w	①+②+③+④+⑦
P. Fang	2008	40/40	Pinaverium bromide+Bifid Triple Viable Capsules	41/42	3m-6y/2m-5y	1m	⑥
Y.C. Gong	2011	30/26	Bifidobacterium tetra viable tablets	33.3±12.3/32.6±11.1	3.3/3.8y	4w	①
L. He	2012	36/30	Bacillus subtilis and Enterococcus bacteria capsule	18-64/18-62	1.2-6/1.5-6y	4w	①
L.J. Hu	2014	50/50	Bifid Triple Viable Capsules	40.3±11.23/45.4±13.29	6m-8y/6m-7y	4w	①
X.G. Hu	2012	35/35	Pinaverium bromide	NR	NR	28d	①+②+④
C.Y. Hua	2013	80/80	Pinaverium bromide	17-27	NR	10d	①+⑥
J.H. Ji	2015	34/32	Montmorillonite+Bacillus subtilis and Enterococcus bacteria capsule	33.2±12.6/32.8±11.0	3.4±1.1/3.5±1.2y	5w	①
Y. Lai	2016	38/32	Bifid Triple Viable Capsules	67.4±13.6/64.5±12.8	3.9±1.5/3.8±1.6	8w	①+②+③+④
A.L. Li	2014	108/100	Combined Bifidobacterium and Lactobacillus Tablets	18-65	NR	8w	①
J.Y. Li	2012	23/22	Pinaverium bromide	42.56±10.71/41.38±11.25	15.72±10.35/15.48±10.52m	2w	①+⑤
G. Liang	2006	43/41	Pinaverium bromide	36.20±3.15/37.11±2.05	3.54±1.25/3.62±1.24y	4w	①
D.X. Liu	2012	59/56	Pinaverium bromide	45/44	1-6y/7m-7y	4w	①
F.X. Liu	2011	42/40	Loperamide	42±12/42±13	1-10/1-11y	4w	①+②+③+④+⑥
L. Liu	2011	24/22	Pinaverium bromide	43.55±13.79/38.70±10.76	6.30±5.52/5.61±5.51y	4w	①+⑤+⑥
C.Q. Lu	2014	34/34	Otilonium bromide	38.0/37.5	4.3/4.6y	4w	①+⑤
D.Y. Ma	2016	23/23	Pinaverium bromide	40/39	NR	4w	①+②+④+⑥
S.L. Peng	2013	34/33	Pinaverium bromide	40.3±11.9	NR	8w	①+②+④+⑤+⑥
L.S. Su	2015	31/31	Pinaverium bromide	35.6±3.4/34.5±3.7	2.9±1.2/2.7±1.5y	2w	①
H.F. Wang	2012	45/45	Dioctahedral smectite	45.2±12.5/43.2±11.7	35.5±12.3/36.7±13.5m	4w	①+⑥
H.Y. Wang	2015	30/30	Trimebutine+Bifid Triple Viable Capsules	41.4±11/42.5±10.6	NR	4w	①
Y.X. Wang	2013	48/50	Pinaverium bromide	27±4.5/29±5.1	3±2.7/3.3±2.4y	1m	①+⑦
Y.Y. Wang	2015	30/30	Pinaverium bromide+Bifid Triple Viable Capsules	46.8/48.9	3.7/3.4y	4w	②+④
C.C. Wang	2015	35/35	NR	40.56±15.02/39.54±13.23	6.80±4.30/8.20±4.69m	4w	①+⑤
P.Y. Wen	2014	42/42	Pinaverium bromide	41.7±11.6/42.4±12.3	36±12.5/37±13.1m	4w	①
J.Y. Wu	2011	30/30	Trimebutine+Bifid Triple Viable Capsules +Vitamin K	40.3±11.23/45.4±13.29	14m-8y/12m-7y	4w	①
Y.N. Wu	2008	55/55	Pinaverium bromide	18-60/16-61	1-30/1-28y	6w	①
J.J. Xu	2012	44/40	Pinaverium bromide	41.8±6.80/43.5±7.3	3.5/4.1y	28d	①+②+③+④+⑤
H.T. Yu	2007	30/30	Bifidobiogen	35.6/36.7	3.7/3.6y	30d	①
F. Zhang	2011	30/30	Dioctahedral smectite	18-69/19-68	1-24/2-23y	4w	①
X.L. Zhang	2017	30/30	Pinaverium bromide	36.7±9.5/36.1±8.2	4.2±1.1/4.5±1.4y	1m	①+⑥
X.D. Zhang	2011	30/30	Oryzanol+Dioctahedral smectite	NR	NR	4w	①
Z.H. Zhou	2010	37/30	Trimebutine	36.2/38.3	4.2/5.5y	14d	①
B.F. Zhuo	2017	43/39	Bifidobacterium tetra viable tablets+Pinaverium bromide	36.3±13.1/35.2±14.3	7.7±5.1/7.4±5.3y	8w	①+②+③+④+⑥

y, year; m, month; w, week; d, day; NR, not reported.
Note: ①the clinical effective rate, ②the score of abdominal pain, ③the score of defecating frequency, ④the score of fecal property, ⑤the score of total symptom, ⑥the adverse effect rate, and ⑦the recurrence rate.